About
Tumor dormancy detection and treatments
Areas of Focus
Categories
DiagnosticsSmall Molecule PharmaceuticalBoston & New England
Clinical Trials (20)
View allTotal Trials
20
As Lead Sponsor
16
As Collaborator
4
Total Enrollment
864
By Phase
PHASE1: 8PHASE2: 7PHASE1/PHASE2: 3PHASE3: 1
By Status
COMPLETED: 12TERMINATED: 5RECRUITING: 2WITHDRAWN: 1
Clinical Trials Pipeline20 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT06285890Collaborator
Phase I Study of HC-7366 for Acute Myeloid Leukemia
PHASE1Recruiting
18 participants
Started: May 20, 2024 · Completed: Dec 31, 2029
NCT06234605Lead Sponsor
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
PHASE1Recruiting
80 participants
Started: Apr 29, 2024 · Completed: Nov 30, 2027
NCT05484011Lead Sponsor
A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
PHASE1Terminated
5 participants
Started: Dec 15, 2022 · Completed: Mar 4, 2024
NCT05121948Lead Sponsor
A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
PHASE1Terminated
35 participants
Started: Feb 23, 2022 · Completed: Mar 1, 2024
NCT05159778Lead Sponsor
Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)
PHASE2Completed
26 participants
Started: Nov 9, 2021 · Completed: Apr 12, 2023
Locations (1)
Headquarters
Boston, MA, United States
Map
Loading map...